

Register by January 22
& SAVE up to \$200!

28th International



Molecular Med TRI-CON

VIRTUAL CONFERENCE & EXPO

Connecting the Precision
Medicine Community

February 16-18, 2021

CONFERENCE PROGRAMS

February 16-17



COVID-19 Diagnostics



Circulating Tumor Cells and
Liquid Biopsy



Immuno-Oncology Biomarkers



Data Analytics & AI for
Precision Medicine: Part 1

February 17-18



COVID-19 Vaccines &
Biotherapeutics



Point-of-Care Diagnostics



Clinical & Translational Biomarkers



Data Analytics & AI for
Precision Medicine: Part 2

Featured & Keynote Speakers



Timothy Stenzel

Director, Office
of In Vitro
Diagnostics and
Radiological
Health, FDA



Hanneke Schuitemaker

VP, Viral Vaccine
Discovery &
Translational
Medicine,
Janssen



Mene Pangalos

EVP,
Biopharmaceuticals
R&D, AstraZeneca



Cecilia Schott

Head, Global Precision
Medicine Strategy
Novartis



Sanjay Gurunathan

VP, Head, Clinical
Sciences
Sanofi



Steven Schachter

RADx Chief,
Professor
Harvard Medical
School



Robert Johnson

Director, Infectious
Disease, BARDA



Hakan Sakul

VP, Head,
Diagnostics
Pfizer

TABLE OF
CONTENTS

#TRICON | [TriConference.com](https://www.TriConference.com)

PREMIER SPONSORS



Table of Contents

CONFERENCE PROGRAMS

February 16-17



COVID-19
Diagnostics



Circulating Tumor
Cells and Liquid
Biopsy



Immuno-Oncology
Biomarkers



Data, Analytics &
AI for Precision
Medicine: Part 1

February 17-18



COVID-19 Vaccines
& Biotherapeutics



Point-of-Care
Diagnostics



Clinical &
Translational
Biomarkers



Data, Analytics &
AI for Precision
Medicine: Part 2

VIEW Sponsorship & Exhibit Opportunities

VIEW Plenary Keynote Program

VIEW Poster Information

VIEW Pathable: Our Virtual Event Platform

VIEW Registration Information




The Tri-Conference captured
the key topics of the moment
combined with a very
diverse set of attendees.

- CCO, OmniSeq



About the TRI-CON

Over the past 27 years, Molecular Medicine Tri-Conference has served as the leading international meeting place for the precision medicine community. As we face the unprecedented task of fighting this pandemic and working together while maintaining social distancing, Cambridge Healthtech Institute once again takes the leadership role of bringing together the life science community at the Tri-Con Virtual 2021. Join international thought leaders to discuss the latest research and technologies in COVID-19 diagnostics, vaccines and biotherapeutics, point-of-care diagnostics, biomarkers and liquid biopsy, data analytics and artificial intelligence. In addition to the leading research and technology presentations you have come to expect at the Tri-Con, now available for on-demand viewing, we have added interactive panel discussions and structured networking opportunities, for a comprehensive 3-day program designed to maximize collaboration and innovation... all without leaving your computer.



The TRICON provided a fantastic experience with presentations on cutting edge science, biomarkers and diagnostics!

- Director, Elsay



Sponsorship & Exhibit Opportunities

Sponsorship opportunities for Tri-Con are available across two programs:

1

Tri-Con MAIN Programs - Virtual sessions will be targeted, deep-dive tracks and paid attendance only. Sponsors have an opportunity to speak within a session and will receive full contact info of all attendees in that session.

2

Tri-Con or breakout COVID-19 Webinar Series - Present your technologies to the Tri-Con audience in advance of (or following) the event! Sponsors will produce a 60 or 90-minute webinar in collaboration with Tri-Con's content developers. 150 leads guaranteed with NO CAP.

For more information, please contact:



Jon Stroup
Senior Manager,
Business Development
781-972-5483
jstroup@healthtech.com

Key Benefits

Premier Sponsor

- Two Presentations
- Full attendee list post-event
- 20 top leads pre-conference
- 6 registrations to main conference sessions – excludes short courses
- 4 registrations with virtual expo access
- Advertising on Diagnostics World News or Bio-IT World
- Virtual Booth with lead gen

Corporate Sponsor

- One Presentation
- Brand your company among thought leaders on the program
- Receive targeted list of leads from your session
- 4 registrations with Main Conference Access – excludes short courses
- 2 registrations with virtual expo access
- Advertising on Diagnostics World News or Bio-IT World
- Virtual Booth with lead gen

Corporate Support Sponsor

- 3 registrations with Main Conference Access – excludes short courses
- 2 registrations with virtual expo access
- Branding as sponsor
- Advertising on Diagnostics World News or Bio-IT World
- Virtual Booth with lead gen

Exhibit Booth

- 2 registrations with Main Conference Access – excludes short courses
- 2 registrations with virtual expo access
- Virtual Booth with lead gen
- Booth Analytics



Sponsors

PREMIER SPONSORS



CORPORATE SPONSORS



CORPORATE SUPPORT SPONSORS



Plenary Keynote Program

Hear from these **Top Minds** in the
Precision Medicine Community this February



Mark T. Esser, PhD, Vice President, Microbial Sciences, BioPharma R&D, AstraZeneca



Robert A. Johnson, PhD, Influenza Director, Biomedical Advanced R&D Authority, US Department of Health & Human Services



Sanjay Gurunathan, MD, Vice President and Head, Global Clinical Department, Sanofi Pasteur



Steven Schachter, MD, Professor, Neurology, Harvard Medical School; Chief Academic Officer and RADx Chief, CIMIT




W. Ian Lipkin, MD, Director, Center for Infection and Immunity, Columbia University



Hanneke Schuitemaker, PhD, Vice President, Viral Vaccine Discovery & Translational Medicine, Janssen Vaccines & Prevention B.V.; Professor, Virology, Amsterdam University Medical Center



Timothy Stenzel, MD, PhD, Director, Office of In Vitro Diagnostics and Radiological Health, FDA



Hakan Sakul, PhD, Vice President and Head, Diagnostics, Pfizer



Mene N. Pangalos, PhD, Executive Vice President Biopharmaceuticals R&D, AstraZeneca

February 16
11:00 am - 1:10 pm

**POWER OF COLLABORATION
IN PANDEMIC RESPONSE:
ADVANCING COVID-19 MOLECULAR
DIAGNOSTICS, VACCINES &
BIOTHERAPEUTICS**

February 17
1:20 - 2:30 pm

**BIG PHARMA'S RESPONSE
TO COVID-19:
RAPID DEVELOPMENT OF
VACCINES AND BIOTHERAPEUTICS**

February 18
11:40 am - 1:25 pm

**PRECISION MEDICINE
AT BIG PHARMA**

[View Full Plenary Keynote Program](#)






FREE Pharma Pass!



**Limited Complimentary Passes For
Big Pharma, available until December 11**

Employees of these companies qualify:
Johnson & Johnson, Roche, Pfizer, Novartis, Merck,
GlaxoSmithKline, Sanofi, AbbVie, Takeda, Bayer, Bristol Myers
Squibb, AstraZeneca, Amgen, Gilead, Eli Lilly, Boehringer
Ingelheim, Novo Nordisk, Teva, Allergan, Biogen.



MEDIA PARTNERS

Official Publication

DiagnosticsWorld

Sponsoring Publications

ADCDIRECTORY

ADC REVIEW

Review

c&en

CIO
APPLICATIONS

CIOReview

Genetic Testing
and Molecular
Biomarkers
Many Area Editors, Inc. Publications

Healthcare Tech
Vivy

Human
Gene Therapy
Many Area Editors, Inc. Publications

NEWS
MEDICAL
LIFE SCIENCES

Pharmacology Directory

Pharmaceutical
Outsourcing

SCIENTIFIC
COMPUTING
WORLD

STAT

Analytical Scientist

The Journal of mHealth

Medicine Maker

The OncoZine Brief

The Pathologist

Lead Sponsoring Publications

aitrends
The Business and Technology of AI

Bio-IT World

CLINICAL
RESEARCH
NEWS
Clinical Trials to the Clinic

Drug
TARGET REVIEW

GEN
Genetic Engineering
& Biotechnology News

INSIGHT
PHARMA REPORTS
Expert Intelligence for Better Decisions

TheScientist
EXPLORING LIFE, INSPIRING INNOVATION

Web Sponsors

1stOncology

B D A N
Big Data Analytics News

Big4Bio

bc Biocompare
The Buyer's Guide for Life Scientists

BioSpace

Gene Therapy Net
Building New
Confidence
Clinical Trials
Vital Nations
Logistics
Solutions

genomeweb

labcompare

mendelspod.com

Sponsoring Organizations and Associations

CLSA
California Life Sciences Association

GEORGIA BIO
The Life Sciences Partnership

samps

XPRIZE

YOLE
Development


pharma
TECH OUTLOOK





Inaugural COVID-19 Diagnostics

Over the past 27 years, the Molecular Medicine Tri-Conference has emerged as a leading annual meeting covering all aspects of molecular diagnostics, including point-of-care and infectious disease diagnostics. As the world faces an unprecedented demand for rapid and accurate SARS-CoV-2 tests, Cambridge Healthtech Institute brings you a new program dedicated to all aspects of COVID-19 diagnostic development, authorization, and implementation.



TUESDAY, FEBRUARY 16

IMPLEMENTATION AND SCALE-UP OF COVID-19 TESTING

8:00 am Lessons Learned from COVID-19: A Framework for Future Success

Karen Kaul MD, PhD, Chair, Department of Pathology and Laboratory Medicine; Duckworth Family Chair, NorthShore University HealthSystem; Clinical Professor, Pathology, University of Chicago Pritzker School of Medicine

8:20 Overcoming Challenges to Diagnostic Testing during a Pandemic

Gregory J. Berry, PhD, D(ABMM), Director, Molecular Diagnostics, Northwell Health System

8:40 Transforming COVID-19 Testing Through BGI/MGI Clinical Lab Partnership Program

Charles Bao, General Manager, BGI Americas

8:50 Sponsored Presentation (Opportunity Available)

9:00 From the Wee Ones and Beyond: Optimal Testing for Maximal Detection of SARS-CoV-2

Jennifer Dien Bard, PhD, D(ABMM), Director, Microbiology and Virology, Children's Hospital Los Angeles; Associate Professor, Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California

9:20 COVID-19 in '21: The State of Diagnostics and New Advances One Year In

Michael J. Mina, PhD, Clinical Fellow, Pathology, Harvard Medical School

9:40 Talk Title to be Announced

Speaker to be Announced



10:10 Panel Discussion: Moderated Q&A

Moderator: Gregory J. Berry, PhD, D(ABMM), Director, Molecular Diagnostics, Northwell Health System

Panelists:

Jennifer Dien Bard, PhD, D(ABMM), Director, Microbiology and Virology, Children's Hospital Los Angeles; Associate Professor, Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California

Michael J. Mina, PhD, Clinical Fellow, Pathology, Harvard Medical School

Speaker to be Announced

Charles Bao, General Manager, BGI Americas

10:35 Session Break - View Our Virtual Exhibit Hall

PLENARY KEYNOTE SESSION: POWER OF COLLABORATION IN PANDEMIC RESPONSE: ADVANCING COVID-19 MOLECULAR DIAGNOSTICS, VACCINES & BIOTHERAPEUTICS



10:55 KEYNOTE PRESENTATION: FDA Update on COVID-19 Molecular Diagnostic Testing

Timothy Stenzel, MD, PhD, Director, Office of In Vitro Diagnostics and Radiological Health, FDA

11:15 Plenary Keynote Introduction (Sponsorship Available)



11:20 KEYNOTE PRESENTATION: RADx Tech: A New Paradigm for MedTech Development

Steven Schachter, MD, Professor, Neurology, Harvard Medical School; Chief Academic Officer and RADx Chief, CIMIT

11:40 Plenary Keynote Introduction (Sponsorship Available)



11:45 KEYNOTE PRESENTATION: From Influenza, to Ebola to Zika: How a Decade of Experience and Investments Prepared

Us to Respond to This Pandemic
Robert A. Johnson, PhD, Influenza Director, Biomedical Advanced R&D Authority, US Department of Health & Human Services



February 16-17, 2021

All times EDT (Eastern Daylight Time)



COVID-19 Diagnostics (Cont.)

12:05 pm Keynote Introduction

Speaker to be Announced



2:40 SARS-CoV-2 Diagnostics by NGS: Interesting Challenges and Scalable Solutions

Jeremy Ellis, Ph.D., Chief Scientific Officer, Fry Laboratories, LLC



4:30 Panel Discussion: Moderated Q&A

Moderator: Dave O'Connor, PhD, UW Medical Foundation Professor, Pathology & Laboratory Medicine, University of Wisconsin-Madison

Panelists:

Esther Babady, PhD, D(ABMM), FIDSA, Section Head, Clinical Microbiology Service, Memorial Sloan Kettering Cancer Center

Mark J. Lee, PhD, Assistant Professor & Assistant Director, DUHS Clinical Microbiology Labs, Duke University

Christopher Mason, PhD, Associate Professor, Physiology and Biophysics; Co-Director, WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine

Robert Schlaberg, MD, PhD, Assistant Professor, Pathology, University of Utah; Medical Director, ARUP Laboratories; Co-Founder & CMO, IDbyDNA

Sheri Wilcox, PhD, Senior Director, Scientific Liaison and Technical Support, SomaLogic, Inc.

Jeremy Ellis, Ph.D., Chief Scientific Officer, Fry Laboratories, LLC

Xin Miao, PhD, Director Assay Development, Mammoth Biosciences

Tim Patno, VP, Product Development, Mammoth Biosciences

Speaker to be Announced, Seegene Technologies Inc.



12:10 KEYNOTE PRESENTATION: Global Public Health Consortium: A Path for Global Biosecurity through Equity and

Transparency

W. Ian Lipkin, MD, Director, Center for Infection and Immunity, Columbia University

12:40 Keynote Panel Discussion: Power of Collaboration in Pandemic Response

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

1:10 Session Break - View Our Virtual Exhibit Hall

MOLECULAR DIAGNOSTICS FOR COVID-19

1:30 COVID-19 Molecular Diagnostics

Esther Babady, PhD, D(ABMM), FIDSA, Section Head, Clinical Microbiology Service, Memorial Sloan Kettering Cancer Center

1:50 Profiling COVID-19, Flu and Other Infectious Diseases through NGS and Target Enriched Metagenomics

Robert Schlaberg, MD, PhD, Assistant Professor, Pathology, University of Utah; Medical Director, ARUP Laboratories; Co-Founder & CMO, IDbyDNA

2:10 Spatial, Multi-Omic, and Shotgun Profiling of COVID-19 Infection and Autopsies

Christopher Mason, PhD, Associate Professor, Physiology and Biophysics; Co-Director, WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine

2:30 The SomaScan® Assay: Biomarker Discovery to Delivery

Sheri Wilcox, PhD, Senior Director, Scientific Liaison and Technical Support, SomaLogic, Inc.



2:50 Session Break - View Our Virtual Exhibit Hall

3:10 The Pitfalls and Challenges in Estimating SARS-CoV-2 Viral Load

Mark J. Lee, PhD, Assistant Professor & Assistant Director, DUHS Clinical Microbiology Labs, Duke University

3:30 WIn-Now: SARS-CoV-2 in Wisconsin Campuses and Communities

Dave O'Connor, PhD, UW Medical Foundation Professor, Pathology & Laboratory Medicine, University of Wisconsin-Madison

3:50 Talk Title to be Announced

Speaker to be Announced,
Seegene Technologies Inc.



4:10 CO- PRESENTATION: Development and

commercialization of a novel high-throughput CRISPR-based SARS-CoV-2 test

Xin Miao, PhD, Director Assay Development, Mammoth Biosciences

Tim Patno, VP, Product Development, Mammoth Biosciences



5:15 Close of Day

WEDNESDAY, FEBRUARY 17

SARS-CoV-2 SEROLOGY TESTING

8:10 am Protein Engineered Sensors for Rapid Quantitation of Antibodies to SARS-CoV-2

James A. Wells, PhD, Professor, Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, University of California, San Francisco

8:30 Sponsored Presentation (Opportunity Available)

[View Full Agenda Online](#)



February 16-17, 2021

All times EDT (Eastern Daylight Time)



COVID-19 Diagnostics (Cont.)

8:50 Serology Testing and SARS CoV-2 Infection: What Have We Learned and Where Are We Headed?

Patricia R. Slev, PhD, Section Chief, Immunology; Medical Director, Immunology Core Laboratory; Associate Professor, University of Utah School of Medicine

9:10 A Rapid Lateral Flow Test Detecting SARS-CoV-2 Neutralizing Antibodies

Jianfu Wang, PhD, CEO, Innovation, Novodiag Inc.



9:30 Application of COVID-19 Antibodies and SARS-CoV-2 Genotyping to Assess Immunity, Re-Infection and Maternal-Fetal

Alan H.B. Wu, PhD, Professor, Laboratory Medicine, University of California, San Francisco; Chief, Chemistry and Toxicology, San Francisco General Hospital

9:50 SARS-CoV-2 Testing: The University of Washington Experience

Alex Greninger, MD, PhD, MS, MPhil, Assistant Professor, Laboratory Medicine, University of Washington

10:10 Session Break - View Our Virtual Exhibit Hall

KEYNOTE PANEL DISCUSSION: WOMEN IN SCIENCE

10:30 Keynote Panel Discussion: Women in Science

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Hanneke Schuitemaker, PhD, Vice President, Viral Vaccine Discovery & Translational Medicine, Janssen Vaccines & Prevention B.V.; Professor, Virology, Amsterdam University Medical Center
Carolyn Compton, MD, PhD, FCAP, Professor, Life Sciences, Arizona State University; Professor of Laboratory Medicine and Pathology, Mayo College of Medicine; CMO, National Biomarker Development Alliance
Malileh Poorfarhani, Director, Digital Health and R&D, Bayer

FUTURE DIRECTIONS IN COVID-19 DIAGNOSTICS

11:00 Update on Advancements in Testing for the Diagnosis of COVID-19

Matthew Binnicker, PhD, Consultant, Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology; Vice Chair of Supply Chain Management, Department of Laboratory Medicine and Pathology; Vice Chair of Practice, Department of Laboratory Medicine/Pathology, Mayo Clinic; Chair, ASM's Professional Development Subcommittee

11:20 Saliva COVID-19 Infection, Viral Load and Immunity Test (SCOVID-19 IVI Test)

David T.W. Wong, DMD, DMSc, Associate Dean of Research, Felix & Mildred Yip Endowed Distinguished Professor, UCLA School of Dentistry

11:40 Talk Title to be Announced

Andrew Brooks, PhD, COO & Director, Technology Development, RUCDR Infinite Biologics; Professor, Genetics, Rutgers University

12:00 pm Sponsored Presentation (Opportunity Available)

12:30 Panel Discussion: Moderated Q&A

Moderator: Matthew Binnicker, PhD, Consultant, Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology; Vice Chair of Supply Chain Management, Department of Laboratory Medicine and Pathology; Vice Chair of Practice, Department of Laboratory Medicine/Pathology, Mayo Clinic; Chair, ASM's Professional Development Subcommittee

Panelists:

James A. Wells, PhD, Professor, Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, University of California, San Francisco
David T.W. Wong, DMD, DMSc, Associate Dean of Research, Felix & Mildred Yip Endowed Distinguished Professor, UCLA School of Dentistry
Alan H.B. Wu, PhD, Professor, Laboratory Medicine, University of California, San Francisco; Chief, Chemistry and Toxicology, San Francisco General Hospital
Jianfu Wang, PhD, CEO, Innovation, Novodiag Inc.

12:55 Session Break - View Our Virtual Exhibit Hall

PLENARY KEYNOTE SESSION: BIG PHARMA'S RESPONSE TO COVID-19: RAPID DEVELOPMENT OF VACCINES AND BIOTHERAPEUTICS



1:20 KEYNOTE PRESENTATION:

Exploring New Therapies for COVID-19: Focus on AstraZeneca's Long-Acting Monoclonal

Antibody Combination

Mark T. Esser, PhD, Vice President, Microbial Sciences, BioPharma R&D, AstraZeneca

1:40 Plenary Keynote Introduction (Sponsorship Available)



1:45 KEYNOTE PRESENTATION:

Janssen's Efforts in the Development of a COVID-19 Vaccine

Hanneke Schuitemaker, PhD,

Vice President, Viral Vaccine Discovery & Translational Medicine, Janssen Vaccines & Prevention B.V.; Professor, Virology, Amsterdam University Medical Center

2:05 Plenary Keynote Introduction (Sponsorship Available)



2:10 KEYNOTE PRESENTATION:

Developing a COVID Vaccine in Ten Months

Sanjay Gurunathan, MD, Vice President and Head, Global Clinical Department, Sanofi Pasteur

2:30 Session Break - View Our Virtual Exhibit Hall

3:00 Close of COVID-19 Diagnostics Conference

[View Full Agenda Online](#)





Inaugural

COVID-19 Vaccines & Biotherapeutics

In response to the urgent need for vaccines and biotherapeutics for the novel coronavirus, Cambridge Healthtech Institute is adding a new meeting dedicated to COVID-19 vaccine development, repurposing of existing therapeutics for COVID-19, and developing new biotherapeutics and antibodies, as well as unraveling the mechanisms of the novel coronavirus and identifying new targets. The COVID-19 Vaccines & Biotherapeutics meeting will present a comprehensive update on the global efforts, clinical trials, research programs, and case studies from industry and academia.



WEDNESDAY, FEBRUARY 17

COVID-19 VACCINES: EMERGING TECHNOLOGIES AND ACCELERATED DEVELOPMENT

3:00 pm Preventing the Next Pandemic: Vaccine Diplomacy in a Time of Antiscience

Peter Hotez, MD, PhD, FASTMH, FAAP, Dean, National School of Tropical Medicine; Professor, Departments of Pediatrics, Molecular Virology & Microbiology; Co-Head, Section of Pediatric Tropical Medicine; Health Policy Scholar, Baylor College of Medicine

3:20 COVID-19 Vaccine Development

Dan Barouch, MD, PhD, William Bosworth Castle Professor of Medicine, Harvard Medical School, Ragon Institute of MGH, MIT, and Harvard; Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center

3:40 Rapid Analytics for Coronavirus Vaccines using the VaxArray Platform



Erica Dawson Dr., Chief Technical Officer, InDevR

3:50 Sponsored Presentation (Opportunity Available)

4:00 Accelerated Development of a Self-Assembling T Cell-Based Vaccine for COVID-19

Mark Poznansky, MD, PhD, Associate Professor, Medicine, Vaccine and Immunotherapy Center, Massachusetts General Hospital

4:20 Skin Targeted Vaccines for COVID-19

Louis D. Falo, Jr., MD, PhD, Chairman, Department of Dermatology, University of Pittsburgh School of Medicine; Professor, Department of Bioengineering, University of Pittsburgh Swanson School of Engineering

4:40 Protein and Newcastle Disease Virus-Based COVID-19 Vaccines

Adolfo Garcia-Sastre, PhD, Professor & Director, Global Health & Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai

5:00 Sponsored Presentation (Opportunity Available)

5:30 Panel Discussion: Moderated Q&A

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Louis D. Falo, Jr., MD, PhD, Chairman, Department of Dermatology, University of Pittsburgh School of Medicine; Professor, Department of Bioengineering, University of Pittsburgh Swanson School of Engineering

Adolfo Garcia-Sastre, PhD, Professor & Director, Global Health & Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai

Sanjay Gurunathan, MD, Vice President and Head, Global Clinical Department, Sanofi Pasteur

Mark Poznansky, MD, PhD, Associate Professor, Medicine, Vaccine and Immunotherapy Center, Massachusetts General Hospital

Erica Dawson Dr., Chief Technical Officer, InDevR

6:00 Close of Day

THURSDAY, FEBRUARY 18

DEVELOPMENT AND REPURPOSING OF BIOTHERAPEUTICS FOR COVID-19

8:00 am Remdesivir for the Treatment of COVID-19

Tomas Cihlar, PhD, Vice President, Virology, Gilead

8:20 COVID-19 Therapeutic Discovery with Supercomputing

Jeremy C. Smith, PhD, Governor's Chair and Director, University of Tennessee/Oak Ridge National Laboratory Center for Molecular Biophysics

8:40 Sponsored Presentation (Opportunity Available)

9:00 The I-SPY COVID Platform Trial: Accelerating Therapeutics for Severe COVID-19

D. Clark Files, MD, Associate Professor, Pulmonary and Critical Care Medicine, Wake Forest School of Medicine

9:20 Session Break - View Our Virtual Exhibit Hall

COVID-19 ANTIBODY THERAPIES

9:40 Human Monoclonal Antibodies for SARS-CoV-2

James E. Crowe Jr., MD, Ann Scott Carell Chair & Professor & Director, Vaccine Center, Vanderbilt University Medical Center



February 17-18, 2021

All times EDT (Eastern Daylight Time)



COVID-19 Vaccines & Biotherapeutics (Cont.)

10:00 SARS-CoV-2 Neutralizing Antibodies for the Treatment of COVID-19

Ajay Nirula, MD, PhD, Vice President, Immunology, Lilly Research Laboratories

10:20 Talk Title to be Announced

Speaker to be Announced



10:50 Panel Discussion: Moderated Q&A

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Tomas Cihlar, PhD, Vice President, Virology, Gilead

James E. Crowe Jr., MD, Ann Scott Carell Chair & Professor & Director, Vaccine Center, Vanderbilt University Medical Center

D. Clark Files, MD, Associate Professor, Pulmonary and Critical Care Medicine, Wake Forest School of Medicine

Ajay Nirula, MD, PhD, Vice President, Immunology, Lilly Research Laboratories

Jeremy C. Smith, PhD, Governor's Chair and Director, University of Tennessee/Oak Ridge National Laboratory Center for Molecular Biophysics

Speaker to be Announced

11:15 Session Break - View Our Virtual Exhibit Hall

PLENARY KEYNOTE SESSION: PRECISION MEDICINE AT BIG PHARMA



11:40 KEYNOTE PRESENTATION: Turning Science into Medicine: The Power of Collaboration

Mene N. Pangalos,
PhD, Executive Vice President
Biopharmaceuticals R&D, AstraZeneca

12:00 pm Plenary Keynote Introduction (Sponsorship Available)



12:05 KEYNOTE PRESENTATION: Talk Title to be Announced

Hakan Sakul, PhD, Vice President and Head, Diagnostics, Pfizer

12:25 Plenary Keynote Introduction (Sponsorship Available)

12:40 Keynote Panel Discussion: Implementing Precision Medicine at Big Pharma

Moderator: Cecilia Schott, PharmD, MBA, Head, Global Precision Medicine Strategy, Oncology Business Unit, Novartis

Panelists:

Hakan Sakul, PhD, Vice President and Head, Diagnostics, Pfizer

Maria C. M. Orr, PhD, FRSB, Head of Precision Medicine, Biopharmaceuticals, AstraZeneca

1:25 Session Break - View Our Virtual Exhibit Hall

COVID-19 DRUG DISCOVERY: UNRAVELING THE BIOLOGY, MECHANISMS AND TARGETS

1:50 Leveraging the Host Response to SARS-CoV-2 to Generate Therapeutics for COVID-19

Benjamin tenOever, PhD, Professor of Microbiology, Irene and Dr. Arthur M. Fishberg Professor of Medicine; Director, Virus Engineering Center for Therapeutics and Research (VECToR); Co-Director, Microbiology Main Training Area, Icahn School of Medicine at Mount Sinai

2:10 Host Genes and Spike Mutations that Mediate SARS-CoV-2 Infection

Neville Sanjana, PhD, Core Faculty Member, New York Genome Center; Assistant Professor, Biology, Neuroscience and Physiology, New York University

2:30 Sponsored Presentation (Opportunity Available)

2:50 Confronting the COVID-19 Pandemic with Supercomputing, Explainable-AI and Systems Biology

Daniel A. Jacobson, PhD, Chief Scientist, Computational Systems Biology, Oak Ridge National Laboratory

3:10 Uncovering New Therapeutic Avenues for SARS-CoV-2 Infection: From Image-Based High-Content Screening to Anti-SARS-CoV-2 Drug Discovery

Francois Jean, PhD, Professor of Virology; Science Advisor, Canadian COVID-19 Therapeutic Task Force; Founder, UBC Facility for Infectious Disease and Epidemic Research, University of British Columbia

3:30 Sponsored Presentation (Opportunity Available)

4:10 Panel Discussion: Moderated Q&A

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Daniel A. Jacobson, PhD, Chief Scientist, Computational Systems Biology, Oak Ridge National Laboratory


Francois Jean, PhD, Professor of Virology; Science Advisor, Canadian COVID-19 Therapeutic Task Force; Founder, UBC Facility for Infectious Disease and Epidemic Research, University of British Columbia

Benjamin tenOever, PhD, Professor of Microbiology, Irene and Dr. Arthur M. Fishberg Professor of Medicine; Director, Virus Engineering Center for Therapeutics and Research (VECToR); Co-Director, Microbiology Main Training Area, Icahn School of Medicine at Mount Sinai

4:30 Close of Conference

[View Full Agenda Online](#)






11th Annual

Circulating Tumor Cells and Liquid Biopsy

Liquid biopsy is a maturing technology for early detection of disease, patient stratification and therapy selection, monitoring response to therapy, and detecting disease recurrence. Cambridge Healthtech Institute's 11th Annual Circulating Tumor Cells and Liquid Biopsy meeting will explore the latest technologies in the detection and molecular characterization of CTCs, cell-free circulating tumor DNA (cfDNA) and circulating extracellular RNA, exosomes and microvesicles, as well as the applications of liquid biopsy in diagnostics and drug development.



TUESDAY, FEBRUARY 16

LIQUID BIOPSY BIOMARKERS FOR ONCOLOGY DRUG DISCOVERY

8:00 am ctDNA in Drug Development

J. Carl Barrett, PhD, Vice President of Translational Science, Oncology, AstraZeneca Pharmaceuticals

8:20 Broad Characterization of Circulating Tumor DNA for Exploratory Biomarker Discovery

Rebecca Leary, PhD, Lab Head, Next Generation Diagnostics, Novartis Institutes for BioMedical Research

8:40 Advancing Highly Multiplexed Liquid and Tissue Biopsy: Introducing RareCyte's Orion Platform

Tad George, PhD, Sr. VP of Biology R&D, R&D, RareCyte, Inc.

RARECYTE

9:00 Liquid Biopsies: Where Are We Now?

Razelle Kurzrock, MD, Director, Center for Personalized Cancer Therapy, University of California, San Diego

9:20 Liquid Biopsy beyond Genomics

Sam Hanash, MD, PhD, Director, Red & Charline McCombs Institute; Evelyn & Sol Rubenstein Distinguished Chair, Cancer Prevention; Professor, Clinical Cancer Prevention-Research, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center

9:40 A Single-Stranded NGS Approach to cfDNA Precision Oncology for Improved Fragmentomic Analyses

Varsha Rao, Director, Clinical R&D, Claret Bioscience LLC



9:50 Talk Title to be Announced

Speaker to be Announced, Qiagen



10:10 Panel Discussion: Moderated Q&A

Moderator: Sam Hanash, MD, PhD, Director, Red & Charline McCombs Institute; Evelyn & Sol Rubenstein Distinguished Chair, Cancer Prevention; Professor, Clinical Cancer Prevention-Research, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Panelists:

Razelle Kurzrock, MD, Director, Center for Personalized Cancer Therapy, University of California, San Diego

Rebecca Leary, PhD, Lab Head, Next Generation Diagnostics, Novartis Institutes for BioMedical Research

Tad George, PhD, Sr. VP of Biology R&D, R&D, RareCyte, Inc.

Varsha Rao, Director, Clinical R&D, Claret Bioscience LLC

Speaker to be Announced, Qiagen

10:35 Session Break - View Our Virtual Exhibit Hall

PLENARY KEYNOTE SESSION: POWER OF COLLABORATION IN PANDEMIC RESPONSE: ADVANCING COVID-19 MOLECULAR DIAGNOSTICS, VACCINES & BIOTHERAPEUTICS



10:55 KEYNOTE PRESENTATION: FDA Update on COVID-19 Molecular Diagnostic Testing

Timothy Stenzel, MD, PhD, Director, Office of In Vitro Diagnostics and Radiological Health, FDA

11:15 Plenary Keynote Introduction (Sponsorship Available)



11:20 KEYNOTE PRESENTATION: RADx Tech: A New Paradigm for MedTech Development

Steven Schachter, MD, Professor, Neurology, Harvard Medical School; Chief Academic Officer and RADx Chief, CIMIT


11:40 Plenary Keynote Introduction (Sponsorship Available)



11:45 KEYNOTE PRESENTATION: From Influenza, to Ebola to Zika: How a Decade of Experience and Investments Prepared

Us to Respond to This Pandemic
Robert A. Johnson, PhD, Influenza Director, Biomedical Advanced R&D Authority, US Department of Health & Human Services





Circulating Tumor Cells and Liquid Biopsy (Cont.)

12:05 pm Keynote Introduction

Speaker to be Announced



2:30 NGS Liquid Biopsy Testing for Solid Tumors: Clinical Trials and Routine Diagnostics

James Yen, PhD, Principal Scientist, Associate
Scientific Director, Pharma Services,
NeoGenomics Laboratories



4:50 Panel Discussion: Moderated Q&A

Moderator: Julia Boguslavsky, Executive Director,
Conferences, Cambridge Healthtech Institute

Panelists:

Viktor A. Adalsteinsson, PhD, Group Leader &
Research Scientist, Blood Biopsy, Broad Institute
Catherine Alix-Panabieres, PhD, Associate
Professor and Director, Laboratory of Rare Human
Circulating Cells (LCCR), University Medical
Center of Montpellier, France
G. Mike Makrigrigios, PhD, Professor of Radiation
Oncology, Dana Farber Cancer Institute and
Harvard Medical School

Speaker to be Announced, Streck, Inc.

James Yen, PhD, Principal Scientist, Associate
Scientific Director, Pharma Services,
NeoGenomics Laboratories

Speaker to be Announced

5:15 Close of Day

WEDNESDAY, FEBRUARY 17

ASSAY DEVELOPMENT FOR LIQUID BIOPSY

8:10 am Talk Title to be Announced

Peter Kuhn, PhD, Director, USC Michelson CSI-
Cancer; Dean's Professor of Biological Sciences;
Professor of Biological Sciences, Medicine,
Biomedical Engineering, and Aerospace and
Mechanical Engineering, University of Southern
California

8:30 High-Purity and High-Sensitivity Rare Cell Isolation with Aliquot Sorting

Daniel T. Chiu, PhD, A. Bruce Montgomery
Professor of Chemistry; Endowed Professor in
Analytical Chemistry; Professor of Bioengineering,
University of Washington

8:50 Multi-Omic Exosome and cf-DNA Biomarker Detection for Liquid Biopsy Diagnostics

Michael J. Heller, PhD, Distinguished Scientist,
Knight Cancer Center/CEDAR/OHSU; Professor
Emeritus & RECAL, UCSD, La Jolla, CA



12:10 KEYNOTE PRESENTATION: Global Public Health Consortium: A Path for Global Biosecurity through Equity and

Transparency

W. Ian Lipkin, MD, Director, Center for
Infection and Immunity, Columbia University

12:40 Keynote Panel Discussion: Power of Collaboration in Pandemic Response

Moderator: Julia Boguslavsky, Executive
Director, Conferences, Cambridge Healthtech
Institute

1:10 Session Break - View Our Virtual Exhibit Hall

LIQUID BIOPSY IN CLINICAL TRIALS

1:30 Expanding Uses for ctDNA in Clinical Trial Design

Darren Hodgson, PhD, Global Project Leader
& Head of Strategy for Translational Medicine,
AstraZeneca

1:50 Development and Validation of a Pan-Cancer ctDNA Assay to Support NCI Clinical Studies

Biswajit Das, PhD, Principal Scientist, Molecular
Characterization, Frederick National Laboratory
for Cancer Research

2:10 Liquid Biopsy in Cancer Patients: A Focus on Metastasis-Initiator Circulating Tumor Cells

Catherine Alix-Panabieres, PhD, Associate
Professor and Director, Laboratory of Rare Human
Circulating Cells (LCCR), University Medical
Center of Montpellier, France

2:50 Session Break - View Our Virtual Exhibit Hall

PRECISION ONCOLOGY: EARLY DETECTION AND MINIMAL RESIDUAL DISEASE

3:10 Ultrasensitive Detection of Minimal Residual Disease

Viktor A. Adalsteinsson, PhD, Group Leader &
Research Scientist, Blood Biopsy, Broad Institute

3:30 Early Detection of Cancer Using Non-Invasive Cell-Free DNA Fragmentation

Victor E. Velculescu, PhD, Professor & Co-Director,
Oncology & Cancer Biology, Johns Hopkins
University

3:50 Talk Title to be Announced

Speaker to be Announced, Streck, Inc.



4:10 New Approaches for Efficient Detection of Cancer Biomarkers in Liquid Biopsies Using NGS

G. Mike Makrigrigios, PhD, Professor of Radiation
Oncology, Dana Farber Cancer Institute and
Harvard Medical School


4:30 Talk Title to be Announced

Speaker to be Announced



[View Full Agenda Online](#)





Circulating Tumor Cells and Liquid Biopsy (Cont.)

9:10 Clinical Development of a Liquid Biopsy Platform to Aid in the Diagnosis and Treatment of Lung Cancer

Robert J. Mattaliano, PhD, COO, Sanmed Diagnostics Inc.



9:30 Single Vesicle Flow Cytometry (vFC) of Tumor-Derived EV Number, Size and Molecular Cargo

John Nolan, PhD, Professor, The Scintillon Institute

9:50 Genome-Wide and Targeted Analysis of Circulating Tumor DNA in Plasma and Urine

Muhammed Murtaza, MBBS, PhD, Visiting Associate Professor, Surgery/Center for Human Genomics and Precision Medicine, University of Wisconsin-Madison

10:10 Session Break - View Our Virtual Exhibit Hall

KEYNOTE PANEL DISCUSSION: WOMEN IN SCIENCE

10:30 Keynote Panel Discussion: Women in Science

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Hanneke Schuitemaker, PhD, Vice President, Viral Vaccine Discovery & Translational Medicine, Janssen Vaccines & Prevention B.V.; Professor, Virology, Amsterdam University Medical Center
Carolyn Compton, MD, PhD, FCAP, Professor, Life Sciences, Arizona State University; Professor of Laboratory Medicine and Pathology, Mayo College of Medicine; CMO, National Biomarker Development Alliance
Malileh Poorfarhani, Director, Digital Health and R&D, Bayer

COLLABORATIVE EFFORTS FOR LIQUID BIOPSY ASSAYS AND DATA

11:00 Cross-Laboratory Evaluation of Multiple ctDNA Sequencing Assays

Joshua Zhihua Xu, PhD, Chief Research to Review, Bioinformatics & Biostatistics, FDA NCTR

11:20 FNIH Biomarkers Consortium Development of Quality Control Materials for ctDNA Assays

Dana Connors, MSc, PMP, Senior Scientific Project Manager, Cancer, Foundation for the National Institutes of Health (NIH)

11:40 The BloodPAC Data Commons

Robert Grossman, PhD, Frederick H. Rawson Distinguished Service Professor in Medicine and Computer Science; Director, The Jim and Karen Frank Center for Translational Data Science, University of Chicago

12:00 pm New Platform for Liquid Biopsy Enables Precise Cancer Diagnosis and CTC Clusters Detection in Early-Stage Breast Cancer

Roberta Carbone, PhD, CSO, Tethis S.p.A



12:30 Panel Discussion: Moderated Q&A

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Dana Connors, MSc, PMP, Senior Scientific Project Manager, Cancer, Foundation for the National Institutes of Health (NIH)
Robert Grossman, PhD, Frederick H. Rawson Distinguished Service Professor in Medicine and Computer Science; Director, The Jim and Karen Frank Center for Translational Data Science, University of Chicago
Robert J. Mattaliano, PhD, COO, Sanmed Diagnostics Inc.
John Nolan, PhD, Professor, The Scintillon Institute
Joshua Zhihua Xu, PhD, Chief Research to Review, Bioinformatics & Biostatistics, FDA NCTR
Roberta Carbone, PhD, CSO, Tethis S.p.A

12:55 Roundtable Discussion: Introducing CTC Assays to Service Laboratories

Introducing CTC Assays to Service Laboratories

Daniel (Dan) O'Shannessy, Founder, TMDx Consulting LLC



PLENARY KEYNOTE SESSION: BIG PHARMA'S RESPONSE TO COVID-19: RAPID DEVELOPMENT OF VACCINES AND BIOTHERAPEUTICS



1:20 KEYNOTE PRESENTATION:

Exploring New Therapies for COVID-19: Focus on AstraZeneca's Long-Acting Monoclonal

Antibody Combination

Mark T. Esser, PhD, Vice President, Microbial Sciences, BioPharma R&D, AstraZeneca

1:40 Plenary Keynote Introduction (Sponsorship Available)



1:45 KEYNOTE PRESENTATION:

Janssen's Efforts in the Development of a COVID-19 Vaccine

Hanneke Schuitemaker, PhD,

Vice President, Viral Vaccine Discovery & Translational Medicine, Janssen Vaccines & Prevention B.V.; Professor, Virology, Amsterdam University Medical Center

2:05 Plenary Keynote Introduction (Sponsorship Available)



2:10 KEYNOTE PRESENTATION:

Developing a COVID Vaccine in Ten Months

Sanjay Gurunathan, MD, Vice

President and Head, Global Clinical Department, Sanofi Pasteur

2:30 Session Break - View Our Virtual Exhibit Hall

3:00 Close of Circulating Tumor Cells and Liquid Biopsy Conference

[View Full Agenda Online](#)





10th Annual

Point-of-Care Diagnostics

The point-of-care diagnostics market has been steadily growing, even before being fueled by the COVID-19 diagnostics wave. Cambridge Healthtech Institute's 10th Annual Point-of-Care Diagnostics meeting will review the latest technological advances, such as microfluidics, nanosensors, and miniaturized devices; as well as integration of POCT in hospitals, pharmacies, critical and home care, mobile settings, and resource-limited settings. Specialized applications, such as COVID-19 testing and antimicrobial resistance testing, will be included.



WEDNESDAY, FEBRUARY 17

POINT-OF-CARE TESTING FOR COVID-19

3:00 pm The Impact of Increasing Prevalence, False Omissions, and Diagnostic Uncertainty on COVID-19 Tests and the Future of Point-of-Care Testing

Gerald Kost, MD, PhD, MS, FAACC, Director, Point-of-Care Testing Center for Teaching and Research (POCT-CTR), University of California, Davis

3:20 Ultrasensitive SARS-CoV-2 Antigen Detection at the Point-of-Care

Ping Wang, PhD, DABCC, FAACC, Professor, Pathology and Laboratory Medicine, University of Pennsylvania; Chief, Clinical Chemistry, Hospital of University of Pennsylvania

3:40 Sponsored Presentation (Opportunity Available)

4:00 COVID-19 POC Diagnostics: Current Opportunities and Considerations for the Future

Larissa May, MD, MSPH, MSHS, Professor, Emergency Medicine; Director, ED and Outpatient Antibiotic Stewardship; Chair, Infection Prevention Committee, UC Davis Health

4:20 Ultrafast PCR Technology for COVID-19 Diagnostics

Hakho Lee, PhD, Associate Professor, Radiology, Harvard Medical School; Director, Biomedical Engineering Program, Center for Systems Biology, Massachusetts General Hospital

4:40 Presentation to be Announced

5:00 Talk Title to be Announced

Speaker to be Announced, Qorvo



5:30 Panel Discussion: Moderated Q&A

Moderator: Larissa May, MD, MSPH, MSHS, Professor, Emergency Medicine; Director, ED and Outpatient Antibiotic Stewardship; Chair, Infection Prevention Committee, UC Davis Health
Panelists:

Ping Wang, PhD, DABCC, FAACC, Professor, Pathology and Laboratory Medicine, University of Pennsylvania; Chief, Clinical Chemistry, Hospital of University of Pennsylvania

Speaker to be Announced, Qorvo

6:00 Close of Day

THURSDAY, FEBRUARY 18

COVID-19 POCT FOR HOME AND PHARMACY SETTINGS

8:00 am UbiNAAT: A Platform for Home Self-Testing of Respiratory Viruses, Including SARS-CoV-2

Paul Yager, PhD, Professor, Department of Bioengineering, University of Washington

8:20 Community-Based SARS-CoV-2 Testing Strategies

Michael E. Klepser, PharmD, FCCP, FIDP, Professor, Ferris State University College of Pharmacy

8:40 Talk Title to be Announced

Speaker to be Announced, SCHOTT MINIFAB



9:00 Early Detection of COVID-19 Using Wearables

Michael Snyder, PhD, Stanford W. Ascherman Professor & Chair, Department of Genetics; Director, Center for Genomics & Personalized Medicine, Stanford University

9:20 Session Break - View Our Virtual Exhibit Hall

CRISPR FOR COVID-19 DIAGNOSTICS

9:40 CRISPR-Based POC Diagnostics for COVID-19

Charles Chiu, MD, PhD, Professor, Laboratory Medicine and Medicine/Infectious Diseases, Director, UCSF-Abbott Viral Diagnostics and Discovery Center, Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine

10:00 The CRISPR Platform for Diagnostics

Janice Chen, PhD, Co-Founder & CTO, Mammoth Biosciences





Point-of-Care Diagnostics (Cont.)

10:50 Panel Discussion: Moderated Q&A

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Janice Chen, PhD, Co-Founder & CTO, Mammoth Biosciences

Charles Chiu, MD, PhD, Professor, Laboratory Medicine and Medicine/Infectious Diseases, Director, UCSF-Abbott Viral Diagnostics and Discovery Center, Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine

Speaker to be Announced, SCHOTT MINIFAB

11:15 Session Break - View Our Virtual Exhibit Hall

PLENARY KEYNOTE SESSION: PRECISION MEDICINE AT BIG PHARMA



11:40 KEYNOTE PRESENTATION: Turning Science into Medicine: The Power of Collaboration

Mene N. Pangalos,
PhD, Executive Vice President
Biopharmaceuticals R&D, AstraZeneca

12:00 pm Plenary Keynote Introduction (Sponsorship Available)



12:05 KEYNOTE PRESENTATION: Talk Title to be Announced

Hakan Sakul, PhD, Vice
President and Head,
Diagnostics, Pfizer

12:25 Plenary Keynote Introduction (Sponsorship Available)

12:40 Keynote Panel Discussion: Implementing Precision Medicine at Big Pharma

Moderator: Cecilia Schott, PharmD, MBA,
Head, Global Precision Medicine Strategy,
Oncology Business Unit, Novartis

Panelists:

Hakan Sakul, PhD, Vice President and Head,
Diagnostics, Pfizer

Maria C. M. Orr, PhD, FRSB, Head of
Precision Medicine, Biopharmaceuticals,
AstraZeneca

1:25 Session Break - View Our Virtual Exhibit Hall

IMPLEMENTING POINT-OF-CARE TESTING IN HEALTH SYSTEMS AND PHARMACIES

1:50 Facing the Challenges of Standardizing POCT: Experiences from a Health System

James Nichols, PhD, DABCC, FACB, Professor of
Pathology, Microbiology and Immunology; Medical
Director, Clinical Chemistry and POCT, Vanderbilt
University School of Medicine

2:10 Closing Care Gap in the Era of COVID – Laboratory Perspective

Hoi-Ying Elsie Yu, PhD, System and Core
Laboratory Director, Chemistry, Toxicology and
Point-of-Care Testing, Geisinger Health System

2:30 Sponsored Presentation (Opportunity Available)

2:50 Scaling POC Testing Across the U.S.: Findings from a Nationwide Sample of Community Pharmacy Leadership on POC Testing Implementation

Kenneth C. Hohmeier, PharmD, Associate
Professor, Director of Community Affairs, PGY-1
Community-based Pharmacy Residency Program
Director, The University of Tennessee Health
Science Center

3:10 What Will the Pharmacy-Based Point-of-Care Testing Market Look Like Post-COVID?

Donald G. Klepser, PhD, MBA, Professor and
Associate Dean for Academic Affairs, College of
Pharmacy, University of Nebraska Medical Center

3:30 Sponsored Presentation (Opportunity Available)

4:10 Panel Discussion: Moderated Q&A

Moderator: Donald G. Klepser, PhD, MBA,
Professor and Associate Dean for Academic
Affairs, College of Pharmacy, University of
Nebraska Medical Center

Panelists:

Kenneth C. Hohmeier, PharmD, Associate
Professor, Director of Community Affairs, PGY-1
Community-based Pharmacy Residency Program
Director, The University of Tennessee Health
Science Center

Hoi-Ying Elsie Yu, PhD, System and Core
Laboratory Director, Chemistry, Toxicology and
Point-of-Care Testing, Geisinger Health System


5:45 Close of Conference

The TRICON has most diverse group of attendees compared to any other conference with bench researchers to bedside practitioners.

- Head of Innovation, Droice Labs

[View Full Agenda Online](#)





6th Annual

Immuno-Oncology Biomarkers



As pharmaceutical and biotechnology companies increase their investment in immuno-oncology programs to facilitate rapid development of novel immunotherapies, there is increasing pressure to discover and validate relevant biomarkers. Cambridge Healthtech Institute's 6th Annual Immuno-Oncology Biomarkers meeting will bring together biomarker experts from industry and academia to address rapid development of predictive and prognostic IO biomarkers, utility of these biomarkers in clinical trials, and their potential as companion diagnostics.



TUESDAY, FEBRUARY 16

PREDICTIVE BIOMARKERS IN IMMUNO-ONCOLOGY

8:00 am PD-L1 2021: All the Critics Are Jumping on the Bandwagon

Kenneth Emancipator, MD, Executive Medical Director, Early Oncology Development, Merck & Co., Inc., Kenilworth, NJ, USA

8:20 What Do We Know about the Mechanism of PD-1 Action?

Adil Daud, MD, Professor, Hematology/Oncology, University of California, San Francisco; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center

8:40 Profiling Exhausted T Cells using Vectra® Polaris™ Multiplex Immunofluorescence Assay in HNSCC

Sara Pollan, PhD, Scientist, Multiplexing, NeoGenomics Laboratories



8:50 Sponsored Presentation (Opportunity Available)

9:00 Predictive Biomarkers for IO in Lung Cancer

Fred Hirsch, MD, PhD, Executive Director, Center for Thoracic Oncology, Tisch Cancer Center; Professor, Medicine and Pathology, Icahn School of Medicine, Mount Sinai NY

9:20 Building a Better Biomarker for Immune Therapy: Lessons Learned from Colon Cancer

Robert Anders, MD, PhD, Associate Professor, Pathology, Johns Hopkins

9:40 How Biospecimen Sourcing Can Impact Your R&D Programs

Vanessa Tumilasci, PhD, Commercial Director, Trans-Hit Biomarkers



10:10 Panel Discussion: Moderated Q&A

Moderator: Kenneth Emancipator, MD, Executive Medical Director, Early Oncology Development, Merck & Co., Inc., Kenilworth, NJ, USA

Panelists:

Robert Anders, MD, PhD, Associate Professor, Pathology, Johns Hopkins

Adil Daud, MD, Professor, Hematology/Oncology, University of California, San Francisco; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center

Fred Hirsch, MD, PhD, Executive Director, Center for Thoracic Oncology, Tisch Cancer Center; Professor, Medicine and Pathology, Icahn School of Medicine, Mount Sinai NY

Vanessa Tumilasci, PhD, Commercial Director, Trans-Hit Biomarkers

10:35 Session Break - View Our Virtual Exhibit Hall

PLENARY KEYNOTE SESSION: POWER OF COLLABORATION IN PANDEMIC RESPONSE: ADVANCING COVID-19 MOLECULAR DIAGNOSTICS, VACCINES & BIOTHERAPEUTICS



10:55 KEYNOTE PRESENTATION: FDA Update on COVID-19 Molecular Diagnostic Testing

Timothy Stenzel, MD, PhD, Director, Office of In Vitro Diagnostics and Radiological Health, FDA

11:15 Plenary Keynote Introduction (Sponsorship Available)



11:20 KEYNOTE PRESENTATION: RADx Tech: A New Paradigm for MedTech Development

Steven Schachter, MD, Professor, Neurology, Harvard Medical School; Chief Academic Officer and RADx Chief, CIMIT

11:40 Plenary Keynote Introduction (Sponsorship Available)



11:45 KEYNOTE PRESENTATION: From Influenza, to Ebola to Zika: How a Decade of Experience and Investments Prepared Us to Respond to This Pandemic

Robert A. Johnson, PhD, Influenza Director, Biomedical Advanced R&D Authority, US Department of Health & Human Services

12:05 pm Keynote Introduction

Speaker to be Announced



12:10 KEYNOTE PRESENTATION: Global Public Health Consortium: A Path for Global Biosecurity through Equity and Transparency

W. Ian Lipkin, MD, Director, Center for Infection and Immunity, Columbia University



February 16-17, 2021

All times EDT (Eastern Daylight Time)



Immuno-Oncology Biomarkers (Cont.)

□ □ □ □ □ □

12:40 Keynote Panel Discussion: Power of Collaboration in Pandemic Response

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

1:10 Session Break - View Our Virtual Exhibit Hall

BIOMARKERS FOR CELL THERAPY AND COMBINATION IMMUNOTHERAPY

1:30 Evaluation of Clinical Response to Cancer Therapy in the Post-PD-1 Treatment Setting

Emmett Schmidt, MD, PhD, Vice President, External Collaborations, Oncology Early Development, Merck

1:50 Integration of Immunotherapy and T Cell Therapy in Precision Oncology Clinical Trials

Apostolia-Maria Tsimberidou, MD, PhD, Professor, Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center

2:10 Predictive Biomarkers of Response and Toxicity to Anti-CD19 CAR T Cell Therapy

John Rossi, PhD, Senior Director, Translational Medicine, Kite, A Gilead Company

2:30 Sponsored Presentation (Opportunity Available)

2:50 Session Break - View Our Virtual Exhibit Hall

3:10 Evaluating Biomarkers of JTX-8064 (Anti-LILRB2/ILT4 Monoclonal Antibody) to Inform Clinical Development

Johan Baeck, MD, Vice President, Clinical Development, Medical Affairs, and Biostatistics and Programming, Jounce Therapeutics

3:30 New Developments in Immuno-Oncology Biomarkers

Andrea Webber, PhD, Assistant Head, Clinical Biomarkers, Translational Oncology, Merck & Co., Inc.

3:50 Sponsored Presentation (Opportunity Available)

4:10 Panel Discussion: Moderated Q&A

Moderator: Emmett Schmidt, MD, PhD, Vice President, External Collaborations, Oncology Early Development, Merck

Panelists:

Johan Baeck, MD, Vice President, Clinical Development, Medical Affairs, and Biostatistics and Programming, Jounce Therapeutics
John Rossi, PhD, Senior Director, Translational Medicine, Kite, A Gilead Company
Apostolia-Maria Tsimberidou, MD, PhD, Professor, Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center
Andrea Webber, PhD, Assistant Head, Clinical Biomarkers, Translational Oncology, Merck & Co., Inc.

Speaker to be Announced

5:15 Close of Day

WEDNESDAY, FEBRUARY 17

BIOMARKERS AND MECHANISM OF RESPONSE AND RESISTANCE TO IMMUNOTHERAPY

8:30 am Integration of Multiplexed Immunofluorescence to Inform Drug Discovery in Immune-Oncology

Darrell R. Borger, PhD, Associate Director, Translational Sciences & ODDU, Takeda Oncology

8:50 The Influence of the Cancer Genome on Immunotherapy

Nadeem Riaz, MD, Associate Director, Immunogenomics and Precision Oncology Platform, Radiation Oncology, Memorial Sloan Kettering Cancer Center

9:10 Talk Title to be Announced

Speaker to be Announced

10x GENOMICS

9:30 Multi-Modality Approach to Predicting and Monitoring Melanoma Immunotherapy Response and Resistance

Genevieve Boland, MD, PhD, Assistant Professor, Surgery; Director, Melanoma Surgery Program, Massachusetts General Hospital

9:50 Immune Mechanisms of PD-1/PD-L1 Resistance

Kathleen Mahoney, MD, PhD, Clinical Instructor, Beth Israel Deaconess Medical Center; Research Fellow, Dana-Farber Cancer Institute

10:10 Session Break - View Our Virtual Exhibit Hall

KEYNOTE PANEL DISCUSSION: WOMEN IN SCIENCE

10:30 Keynote Panel Discussion: Women in Science

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Hanneke Schuitemaker, PhD, Vice President, Viral Vaccine Discovery & Translational Medicine, Janssen Vaccines & Prevention B.V.; Professor, Virology, Amsterdam University Medical Center
Carolyn Compton, MD, PhD, FCAP, Professor, Life Sciences, Arizona State University; Professor of Laboratory Medicine and Pathology, Mayo College of Medicine; CMO, National Biomarker Development Alliance
Malileh Poorfarhani, Director, Digital Health and R&D, Bayer

LIQUID BIOPSY IN IMMUNO-ONCOLOGY

11:00 Small Extracellular Vesicles as Promising Biomarkers in Immuno-Oncology

Theresa L. Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, University of Pittsburgh

[View Full Agenda Online](#)



February 16-17, 2021

All times EDT (Eastern Daylight Time)



Immuno-Oncology Biomarkers (Cont.)

□ □ □ □ □ □

11:20 cfmiR in Monitoring IO Therapies in Melanoma

Dave S.B. Hoon, Professor, Director Translational Research JWCI & Director, Translational Molecular Medicine & Genomic Sequencing Center, JWCI Providence Health Systems

11:40 Role of Central Memory CD8+ T Cells in Cancer Immunotherapy

Holden T. Maecker, PhD, Research Professor, Microbiology & Immunology, Stanford University

12:00 pm Sponsored Presentation (Opportunity Available)

12:30 Panel Discussion: Moderated Q&A

Moderator: Theresa L. Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, University of Pittsburgh

Panelists:

Darrell R. Borger, PhD, Associate Director, Translational Sciences & ODDU, Takeda Oncology

Dave S.B. Hoon, Professor, Director Translational Research JWCI & Director, Translational Molecular Medicine & Genomic Sequencing Center, JWCI Providence Health Systems

Holden T. Maecker, PhD, Research Professor, Microbiology & Immunology, Stanford University

12:55 Session Break - View Our Virtual Exhibit Hall

PLENARY KEYNOTE SESSION: BIG PHARMA'S RESPONSE TO COVID-19: RAPID DEVELOPMENT OF VACCINES AND BIOTHERAPEUTICS



1:20 KEYNOTE PRESENTATION:

Exploring New Therapies for COVID-19: Focus on AstraZeneca's Long-Acting Monoclonal

Antibody Combination

Mark T. Esser, PhD, Vice President, Microbial Sciences, BioPharma R&D, AstraZeneca

1:40 Plenary Keynote Introduction (Sponsorship Available)



1:45 KEYNOTE PRESENTATION:

Janssen's Efforts in the Development of a COVID-19 Vaccine

Hanneke Schuitemaker, PhD, Vice President, Viral Vaccine Discovery & Translational Medicine, Janssen Vaccines & Prevention B.V.; Professor, Virology, Amsterdam University Medical Center

2:05 Plenary Keynote Introduction (Sponsorship Available)



2:10 KEYNOTE PRESENTATION:

Developing a COVID Vaccine in Ten Months

Sanjay Gurunathan, MD, Vice President and Head, Global Clinical Department, Sanofi Pasteur

2:30 Session Break - View Our Virtual Exhibit Hall

3:00 Close of Immuno-Oncology Biomarkers Conference

[View Full Agenda Online](#)





11th Annual

Clinical & Translational Biomarkers

The promise of precision medicine has been driven by the need to accurately predict patient response to therapy, while ensuring drug efficacy and safety. Reducing costs and the time required for drug development are also driving forces in the use of biomarkers. Cambridge Healthtech Institute's 11th Annual Clinical & Translational Biomarkers meeting will cover novel biomarker discovery, clinical and analytical biomarker validation, and the role of biomarkers in clinical decision making.



WEDNESDAY, FEBRUARY 17

BIOMARKERS TO SUPPORT CLINICAL TRIALS DURING PANDEMIC

3:00 pm The Challenges in Conducting Infectious Disease Clinical Trials in Low- and Middle-Income Countries: The Reality of Bioassays that Work under a Tree

Russell S. Weiner, PhD, Head Bioanalysis, Biomarker Development & Diagnostics, Bill & Melinda Gates Medical Research Institute

3:20 Talk Title to be Announced

Kristina McGuire, PhD, Senior Director, Precision Medicine, Regeneron Pharmaceuticals, Inc.

3:40 Clinical Trial Assay & CDx Development in the era of Precision Medicine – Planning for Success

Katarina Wikstrom, PhD, Head of US Operations, Almac Group

4:00 Year of 2021: A Tipping Point of Bringing IO Biomarkers into Real-World Clinical Consideration

Zhen Su, MD, MBA, Senior Vice President, Head of US & Global Oncology Franchise, EMD Serono, a business of Merck KGaA, Darmstadt, Germany

4:20 Presentation to be Announced

4:40 Translational Safety, Strategic Gaps, and Biomarker Examples

Shashi Ramaiah, PhD, Executive Director, Global Head of Biomarkers, Drug Safety R&D, Pfizer

5:00 Talk Title to be Announced

Speaker to be Announced

5:30 Panel Discussion: Moderated Q&A

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Kristina McGuire, PhD, Senior Director, Precision Medicine, Regeneron Pharmaceuticals, Inc.

Russell S. Weiner, PhD, Head Bioanalysis, Biomarker Development & Diagnostics, Bill & Melinda Gates Medical Research Institute

Katarina Wikstrom, PhD, Head of US Operations, Almac Group

6:00 Close of Day



8:40 Transforming Surveillance into Analytics for Predictive Biomarkers and Clinical Diagnostics in Oncology

Mark Gramling, PhD, Director of Oncology, Larvol

8:50 Sponsored Presentation (Opportunity Available)

9:00 Global Implementation of Companion Diagnostic Solutions: A Changing Landscape

Marielena Mata, PhD, Senior Director and Diagnostic Lead, Oncology Program, Pfizer

9:20 Session Break - View Our Virtual Exhibit Hall

9:40 Global and Regional Considerations for Developing Patient Selection Markers into Companion Diagnostics in Oncology Drug Development

Masayuki Kanai, PhD, Director & Global Companion Diagnostics Leader, Clinical Biomarkers & Translational Science, Daiichi Sankyo Inc.

10:00 Talk Title to be Announced

Elizabeth B. Somers, Senior Director, Diagnostic Pathway Lead, Alzheimer's Disease Franchise, Eisai Inc.

10:20 Sponsored Presentation (Opportunity Available)

THURSDAY, FEBRUARY 18

PRECISION MEDICINE AND COMPANION DIAGNOSTICS AT BIG PHARMA

8:00 Drug Combinations, Industry Alliances and Multiple Biomarkers: The New Era of Precision Medicine, Are We Ready?

Lourdes Barrera, PhD, Senior Director, Precision Medicine, Oncology Business Unit, Novartis

8:20 Navigating the Diagnostic Regulatory Landscape from a Single Biomarker to Complex Signatures

Eunice Lee, PhD, Executive Director, Global Regulatory Affairs, Merck & Co, Inc.





Clinical & Translational Biomarkers (Cont.)

10:50 Panel Discussion: Moderated Q&A

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Masayuki Kanai, PhD, Director & Global Companion Diagnostics Leader, Clinical Biomarkers & Translational Science, Daiichi Sankyo Inc.

Mark Gramling, PhD, Director of Oncology, Larvol
Marielena Mata, PhD, Senior Director and Diagnostic Lead, Oncology Program, Pfizer
Lourdes Barrera, PhD, Senior Director, Precision Medicine, Oncology Business Unit, Novartis

11:15 Session Break - View Our Virtual Exhibit Hall

PLENARY KEYNOTE SESSION: PRECISION MEDICINE AT BIG PHARMA



11:40 KEYNOTE PRESENTATION:

Turning Science into Medicine: The Power of Collaboration

Mene N. Pangalos,
PhD, Executive Vice President
Biopharmaceuticals R&D, AstraZeneca

12:00 pm Plenary Keynote Introduction (Sponsorship Available)



12:05 KEYNOTE PRESENTATION:

Title to be Announced

Hakan Sakul, PhD, Vice President and Head, Diagnostics, Pfizer

12:25 Plenary Keynote Introduction (Sponsorship Available)

12:40 Keynote Panel Discussion: Implementing Precision Medicine at Big Pharma

Moderator: Cecilia Schott, PharmD, MBA, Head, Global Precision Medicine Strategy, Oncology Business Unit, Novartis

Panelists:

Hakan Sakul, PhD, Vice President and Head, Diagnostics, Pfizer
Maria C. M. Orr, PhD, FRSB, Head of Precision Medicine, Biopharmaceuticals, AstraZeneca

1:25 Session Break - View Our Virtual Exhibit Hall

BIOMARKERS IN ONCOLOGY DRUG DEVELOPMENT

1:50 Empowering Patients & Physicians: A Novel Clinical Trial for Molecular Disease Characterization

Kristin Blouch, Director, Disease Characterization & Strategy, Experimental Medicine Unit, GlaxoSmithKline

2:10 Utility of Monitoring a Non-Genomic Biomarker for Prediction of Clinical Efficacy in Oncology

Michael Baratta, BA/MCAHPM, Scientific Director and Chief of Staff, Clinical Biomarker Development Innovation, Takeda

2:30 Sponsored Presentation (Opportunity Available)

2:50 Biomarkers of Sensitivity and Resistance to Antibody-Drug Conjugates (ADCs)

Monica Motwani, PhD, Director (Research Fellow), Translational Oncology, Abbvie

3:10 Challenges and Benefits of Biomarker-Selected Patient Populations in Oncology Trials

Julia Markensohn, PhD, Principal Scientist, Merck & Co.

3:30 Session Break - View Our Virtual Exhibit Hall

BIOMARKER DISCOVERY AND ASSAY DEVELOPMENT

3:50 am Preanalytics: The Immense Imprecision Impeding Precision Medicine

Carolyn Compton, MD, PhD, FCAP, Professor, Life Sciences, Arizona State University; Professor of Laboratory Medicine and Pathology, Mayo College of Medicine; CMO, National Biomarker Development Alliance

4:10 Development of a Genomics Consortium of Academic Laboratories

Jennifer Morrisette, PhD, Director, Clinical CytoGenomics Laboratory; Associate Professor, Pathology, University of Pennsylvania

4:30 Harnessing Peripheral Blood Signals as Biomarkers for Neurodegenerative Diseases

Aparna Vasanthakumar, PhD, Principal Research Scientist, AbbVie Inc.

4:50 Biomarkers vs. Comprehensive Genomics to Guide Therapy in Advanced Cancers

George Vasmatzis, PhD, Assistant Professor Lab Medicine & Co-Director, Biomarker Discovery Program, Mayo Clinic & Foundation

5:20 Panel Discussion: Moderated Q&A

Moderator: Carolyn Compton, MD, PhD, FCAP, Professor, Life Sciences, Arizona State University; Professor of Laboratory Medicine and Pathology, Mayo College of Medicine; CMO, National Biomarker Development Alliance

Panelists:

Julia Markensohn, PhD, Principal Scientist, Merck & Co.

Jennifer Morrisette, PhD, Director, Clinical CytoGenomics Laboratory; Associate Professor, Pathology, University of Pennsylvania

Monica Motwani, PhD, Director (Research Fellow), Translational Oncology, Abbvie

Aparna Vasanthakumar, PhD, Principal Research Scientist, AbbVie Inc.

5:45 Close of Conference

[View Full Agenda Online](#)



13th Annual



Data, Analytics & AI for Precision Medicine: Part 1

For precision medicine to reach its true potential, diagnostics, pharmaceutical and clinical organizations must develop a comprehensive data strategy at the executive level in order to realize the true potential of data-driven technologies. This conference program will explore the business models and strategies required to derive actionable insights from patient data to enhance lab processes and improve outcomes. Key topics covered include strategies to facilitate partnerships and collaboration; hiring the right talent; implementing data management tools; and standardization, policy and privacy considerations. With these technologies promising to enable interoperability and integration of siloed data from varied sources, are we a step closer to cutting-edge insights and predictions to enable individualised care? This conference program is aimed at those executives looking to leverage patient data and enhance processes from pharma/biotech companies; clinical labs; lab service suppliers/CROs; diagnostic developers; medical device manufacturers, and technology/software providers, tackling this bold new data challenge and advancing the field of precision medicine.



TUESDAY, FEBRUARY 16

A DIVERSE LOOK AT DATA & AI FOR PRECISION MEDICINE

8:20 am Meaningful Use of Machine Learning in Handling Data to Insight in Genetics and Genomics Laboratory

Felicitas L. Lacbawan, Vice President/Executive Medical Director, Advanced Diagnostics, Quest Diagnostics Nichols Institute

8:40 Sponsored Presentation (Opportunity Available)

9:00 Advancing Precision Medicine for Castleman Disease: Lessons Learned from Chasing My Cure

David C. Fajgenbaum, Research Assistant Professor, Translational Medicine & Human Genetics, University of Pennsylvania Hospital

9:40 Sponsored Presentation (Opportunity Available)

10:10 Panel Discussion: Moderated Q&A

Moderator: Dominie Roberts, Conference Director, Cambridge Innovation Institute
Panelists:

David C. Fajgenbaum, Research Assistant Professor, Translational Medicine & Human Genetics, University of Pennsylvania Hospital
Felicitas L. Lacbawan, Vice President/Executive Medical Director, Advanced Diagnostics, Quest Diagnostics Nichols Institute

10:35 Session Break - View Our Virtual Exhibit Hall

PLENARY KEYNOTE SESSION: POWER OF COLLABORATION IN PANDEMIC RESPONSE: ADVANCING COVID-19 MOLECULAR DIAGNOSTICS, VACCINES & BIOTHERAPEUTICS



10:55 KEYNOTE PRESENTATION: FDA Update on COVID-19 Molecular Diagnostic Testing

Timothy Stenzel, MD, PhD, Director, Office of In Vitro Diagnostics and Radiological Health, FDA

11:15 Plenary Keynote Introduction (Sponsorship Available)



11:20 KEYNOTE PRESENTATION: RADx Tech: A New Paradigm for MedTech Development

Steven Schachter, MD, Professor, Neurology, Harvard Medical School; Chief Academic Officer and RADx Chief, CIMIT

11:40 Plenary Keynote Introduction (Sponsorship Available)



11:45 KEYNOTE PRESENTATION: From Influenza, to Ebola to Zika: How a Decade of Experience and Investments Prepared Us to Respond to This Pandemic

Robert A. Johnson, PhD, Influenza Director, Biomedical Advanced R&D Authority, US Department of Health & Human Services

12:05 pm Keynote Introduction

Speaker to be Announced



12:10 KEYNOTE PRESENTATION: Global Public Health Consortium: A Path for Global Biosecurity through Equity and Transparency

W. Ian Lipkin, MD, Director, Center for Infection and Immunity, Columbia University

12:40 Keynote Panel Discussion: Power of Collaboration in Pandemic Response

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

1:10 Session Break - View Our Virtual Exhibit Hall

ACHIEVING PRECISION MEDICINE THROUGH EFFECTIVE PARTNERSHIPS AND COLLABORATION

1:30 Executive Panel Discussion: Harnessing the Power of AI in the Move to True Precision Medicine through Collaboration

Moderator: Matthew Lungren, Assistant Professor of Radiology & Associate Director, Center for AI in Medicine & Imaging, Stanford University

Panelists:

Malileh Poorfarhani, Director, Digital Health and R&D, Bayer
Faisal Khan, PhD, Executive Director, Advanced Analytics & AI, AstraZeneca Pharmaceuticals, Inc.
Andrea DeSouza, Senior Director, Eli Lilly & Company



February 16-17, 2021

All times EDT (Eastern Daylight Time)



Data, Analytics & AI for Precision Medicine: Part 1 (Cont.)

2:10 Integrating Data for Cell Therapy Research and Early Development

Ajay Shah, PhD, MBA, Executive Director & Head of IT for Translational Medicine, Bristol-Myers Squibb

2:30 Sponsored Presentation (Opportunity Available)

2:50 The Path from Big Data to Precision Medicine

Emma Huang, Director of Data Sciences External Innovation at the California Innovation Center, Johnson & Johnson

3:30 Panel Discussion: Moderated Q&A

Moderator: Dominie Roberts, Conference Director, Cambridge Innovation Institute

Panelists:

Matthew Lungren, Assistant Professor of Radiology & Associate Director, Center for AI in Medicine & Imaging, Stanford University

Ajay Shah, PhD, MBA, Executive Director & Head of IT for Translational Medicine, Bristol-Myers Squibb

Emma Huang, Director of Data Sciences External Innovation at the California Innovation Center, Johnson & Johnson

3:50 Close of Day

WEDNESDAY, FEBRUARY 17

10:10 am Session Break - View Our Virtual Exhibit Hall

KEYNOTE PANEL DISCUSSION: WOMEN IN SCIENCE

10:30 Keynote Panel Discussion: Women in Science

Moderator: Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

Panelists:

Hanneke Schuitemaker, PhD, Vice President, Viral Vaccine Discovery & Translational Medicine, Janssen Vaccines & Prevention B.V.; Professor, Virology, Amsterdam University Medical Center

Carolyn Compton, MD, PhD, FCAP, Professor, Life Sciences, Arizona State University; Professor of Laboratory Medicine and Pathology, Mayo College of Medicine; CMO, National Biomarker Development Alliance

Malileh Poorfarhani, Director, Digital Health and R&D, Bayer

REQUIRED TOOLS & WINNING STRATEGIES

11:00 Talk Title to be Announced

Andrea DeSouza, Senior Director, Eli Lilly & Company

11:20 Patient Centricity as a Prerequisite for Precision Medicine and Machine Learning in Rare Diseases

Alexander Sherman, Director, Center for Innovation and Bioinformatics, Massachusetts General Hospital

11:40 Building Multi-Disciplinary Teams for Clinical Machine Intelligence Applications

Matthew Lungren, Assistant Professor of Radiology & Associate Director, Center for AI in Medicine & Imaging, Stanford University

12:00 pm Sponsored Presentation (Opportunity Available)

12:30 Panel Discussion: Moderated Q&A

Moderator: Dominie Roberts, Conference Director, Cambridge Innovation Institute

Panelists:

Alexander Sherman, Director, Center for Innovation and Bioinformatics, Massachusetts General Hospital

Matthew Lungren, Assistant Professor of Radiology & Associate Director, Center for AI in Medicine & Imaging, Stanford University

Andrea DeSouza, Senior Director, Eli Lilly & Company

12:55 Session Break - View Our Virtual Exhibit Hall

PLENARY KEYNOTE SESSION: BIG PHARMA'S RESPONSE TO COVID-19: RAPID DEVELOPMENT OF VACCINES AND BIOTHERAPEUTICS



1:20 KEYNOTE PRESENTATION: Exploring New Therapies for COVID-19: Focus on AstraZeneca's Long-Acting Monoclonal

Antibody Combination

Mark T. Esser, PhD, Vice President, Microbial Sciences, BioPharma R&D, AstraZeneca

1:40 Plenary Keynote Introduction (Sponsorship Available)



1:45 KEYNOTE PRESENTATION: Janssen's Efforts in the Development of a COVID-19 Vaccine

Hanneke Schuitemaker, PhD, Vice President, Viral Vaccine Discovery & Translational Medicine, Janssen Vaccines & Prevention B.V.; Professor, Virology, Amsterdam University Medical Center

2:05 Plenary Keynote Introduction (Sponsorship Available)

[View Full Agenda Online](#)



February 16-17, 2021

All times EDT (Eastern Daylight Time)



Data, Analytics & AI for Precision Medicine: Part 1 (Cont.)



**2:10 KEYNOTE
PRESENTATION:**

**Developing a COVID
Vaccine in Ten Months**

*Sanjay Gurunathan, MD, Vice
President and Head, Global*

Clinical Department, Sanofi Pasteur

**2:30 Session Break - View Our Virtual
Exhibit Hall**

**3:00 Close of Data, Analytics & AI for
Precision Medicine: Part 1 Conference**



Most cutting-edge molecular medicine
conference in the world!

- *Senior Director, Luminex Corp*



[View Full Agenda Online](#)






13th Annual

Data, Analytics & AI for Precision Medicine: Part 2

To meet the challenge of collecting, integrating and interpreting vast amounts of disparate and unstructured data, the implementation of effective and scalable lab automation and data management tools; as well as complex analytics and predictive models, such as AI, ML and deep learning, is paramount. As a continuation from Part 1, Part 2 of the 'Data, Analytics & AI for Precision Medicine' conference program will explore the practical steps necessary for diagnostics, pharmaceutical and clinical organizations to successfully implement and leverage data-driven technologies, to advance precision medicine. This conference program is aimed at those looking to enhance lab processes and leverage data to enhance efficiencies and improve outcomes, from pharma/biotech companies; clinical labs; lab service suppliers/CROs; diagnostic developers; medical device manufacturers, and technology/software providers, tackling this bold new data challenge and advancing the field of precision medicine.



WEDNESDAY, FEBRUARY 17

PRACTICAL STEPS TO TECHNOLOGY IMPLEMENTATION

3:00 pm Panel Discussion: Tackling the Challenges Hindering AI Adoption: Action Steps to Accelerate Innovation (Led by: Alliance for Artificial Intelligence in Healthcare (AAIH))

Moderator: Sean Khozin, Vice President & Global Head, Data Strategy, Johnson & Johnson

Panelists:

Angeli Möller, Appointed as Head of Pharma Informatics International, Roche

Maria L. Pineda, PhD, CEO & Co-Founder, Envisagenics Inc.

David Ruau, Head of Global Data Asset and Decision Science, Bayer

Meri Williams, CTO, Healx

3:40 Sponsored Presentation (Opportunity Available)

4:00 pm Effective Regulation in the Age of Exponential Technologies

M. Khair ElZarrad K. ElZarrad, PhD, Deputy Director Office of Medical Policy, Center for Drug Evaluation & Research, FDA CDER

4:20 Leveraging AI/ML and RNA-seq Data to Accelerate Target & Therapeutic Discovery

Maria L. Pineda, PhD, CEO & Co-Founder, Envisagenics Inc.

5:00 Sponsored Presentation (Opportunity Available)

5:30 Panel Discussion: Moderated Q&A

Moderator: Dominie Roberts, Conference Director, Cambridge Innovation Institute

Panelists:

Sean Khozin, Vice President & Global Head, Data Strategy, Johnson & Johnson

M. Khair ElZarrad K. ElZarrad, PhD, Deputy Director Office of Medical Policy, Center for Drug Evaluation & Research, FDA CDER

Maria L. Pineda, PhD, CEO & Co-Founder, Envisagenics Inc.

6:00 Close of Day

THURSDAY, FEBRUARY 18

MAKING SENSE OF DATA: A DEEP-DIVE

8:00 am Deep Learning-Based Cancer Patient Stratification Is Here

Altuna Akalin, PhD, Group Leader, Bioinformatics Platform, Max Delbrück Center for Molecular Medicine

8:20 Overcoming Biomedical Reductionism with Systems Thinking

Sean Khozin, Vice President & Global Head, Data Strategy, Johnson & Johnson

8:40 Sponsored Presentation (Opportunity Available)

9:00 Successfully Integrating and Interpreting Multi-Omic Datasets

Kristin G. Beaumont, PhD, Assistant Professor, Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai

9:20 Session Break - View Our Virtual Exhibit Hall

10:00 Leveraging Transcriptomics and Clinical Data to Identify Therapeutic Candidates for COVID-19

Marina Sirota, PhD, Assistant Professor, Institute for Computational Health Sciences, University of California San Francisco

10:20 Sponsored Presentation (Opportunity Available)

10:50 Panel Discussion: Moderated Q&A

Moderator: Dominie Roberts, Conference Director, Cambridge Innovation Institute

Panelists:

Altuna Akalin, PhD, Group Leader, Bioinformatics Platform, Max Delbrück Center for Molecular Medicine

Kristin G. Beaumont, PhD, Assistant Professor, Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai

Sean Khozin, Vice President & Global Head, Data Strategy, Johnson & Johnson

Marina Sirota, PhD, Assistant Professor, Institute for Computational Health Sciences, University of California San Francisco

11:15 Session Break - View Our Virtual Exhibit Hall



February 17-18, 2021

All times EDT (Eastern Daylight Time)



Data, Analytics & AI for Precision Medicine: Part 2 (Cont.)

PLENARY KEYNOTE SESSION: PRECISION MEDICINE AT BIG PHARMA



11:40 KEYNOTE PRESENTATION: Turning Science into Medicine: The Power of Collaboration

Mene N. Pangalos,
PhD, Executive Vice President
Biopharmaceuticals R&D, AstraZeneca

12:00 pm Plenary Keynote Introduction
(Sponsorship Available)



12:05 KEYNOTE PRESENTATION: Talk Title to be Announced Hakan Sakul, PhD, Vice President and Head, Diagnostics, Pfizer

12:25 Plenary Keynote Introduction
(Sponsorship Available)

12:40 Keynote Panel Discussion: Implementing Precision Medicine at Big Pharma

Moderator: Cecilia Schott, PharmD, MBA,
Head, Global Precision Medicine Strategy,
Oncology Business Unit, Novartis
Panelists:
Hakan Sakul, PhD, Vice President and Head,
Diagnostics, Pfizer
Maria C. M. Orr, PhD, FRSB, Head of
Precision Medicine, Biopharmaceuticals,
AstraZeneca

1:25 Session Break - View Our Virtual
Exhibit Hall

AI IN IMAGING

1:50 Building a Creative & Collaborative Network for Medical Imaging & Associated Clinical Data with AI

Krishna Kandarpa, MD, PhD, Director of
Research Sciences and Strategic Directions,
National Institute of Biomedical Imaging and
Bioengineering (NIBIB)

2:10 Deep-Learning Assisted Evaluation of the Fetal Heart in Health and Disease

Rima Arnaout, Assistant Adjunct Professor,
Cardiology, University of California San Francisco

3:30 Sponsored Presentation
(Opportunity Available)

3:50 Panel Discussion: Moderated Q&A

Moderator: Dominie Roberts, Conference Director,
Cambridge Innovation Institute

Panelists:

Krishna Kandarpa, MD, PhD, Director of
Research Sciences and Strategic Directions,
National Institute of Biomedical Imaging and
Bioengineering (NIBIB)

Rima Arnaout, Assistant Adjunct Professor,
Cardiology, University of California San Francisco

5:45 Close of Conference

The Tri-Conference is a worthwhile event because it gave me a nice cross-section view of the field of cloud and biomedicine in academic and commercial spaces.


- Associate Research Scientist, Taylor Laboratory,
Computational Biology and Genomics, Johns Hopkins University

[View Full Agenda Online](#)





PRESENT A VIRTUAL POSTER AND SAVE \$50



Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the virtual poster sessions. To ensure your poster presentation is included in the conference materials, your full submission must be received, and your registration paid in full by **January 15, 2021**.

Register and indicate that you would like to present a virtual poster. Once your registration has been fully processed, we will send an email with a unique link and instructions for submitting your abstract and other materials. Please see website for more information.

www.TriConference.com/Posters-Info

Reasons you should present your research poster at this conference:

- Your research will be seen by our international delegation, representing leaders from top pharmaceutical, biotech, academic and government institutions
- Discuss your research and collaborate with other attendees during designated chat times
- Your poster presentation will be published on our conference platform
- Receive \$50 off your registration (product or service providers do not qualify for discount)

Virtual scientific poster presentation materials will include:

- Poster title
- Text-only abstract. It can be an in-depth, one-page abstract, or just a short description.
- 3-5 minute voice-over PowerPoint presentation. You may substitute the PowerPoint with a one-page, static PDF of your poster.

[Learn More](#)



Pathable is a robust event platform, designed to enhance the online conference experience and selected by CHI for its full range of opportunities to present, target, connect and **expand your reach.**




Company Profiles

Attendees can search & filter from an alphabetical listing to easily find your company listing.

PROFILE HIGHLIGHTS INCLUDE:

- Logo Branding
- Company Description
- Offerings Tags
- Upload Videos & Files
- Showcases Sponsored Sessions
- Displays Booth Personnel
- Networking Options



Sponsored Sessions & Breakout Discussions

Stand out with consistent logo branding everywhere your talk or breakout is listed.

FURTHER DETAILS WITHIN EACH AGENDA ITEM INCLUDE:

- Abstracts
- Direct Link to Your Live or Pre-Recorded Presentation
- Link to Speaker Profile
- Files Relevant to Your Presentation
- Polls




Networking


The People section makes it easy to find the right connections. Search or filter an alphabetical listing to view attendee profiles and start networking.

WAYS TO CONNECT INCLUDE:

- Create a Want to Meet List
- Send a Message Request for a 1:1 Meeting



All conference content will be available **On-Demand** post the live event



CHI Virtual Events get Rave Reviews

“ Given the challenging logistics and infrastructure for a virtual conference during the COVID pandemic, this was an exceptional experience, and I was impressed with the efforts by the CHI staff and their ability to pivot to and host an impactful and connecting virtual conference. ”

*Charles Wartchow, Principal Investigator,
Novartis Institutes for BioMedical Research*



“ A very well-structured virtual conference that met the participants' requirements whilst creating a stimulating environment for networking. ”

*Shahid Uddin, Director, Drug Product,
Formulation & Stability, Immunocore*



Learn More at
Healthtech.com

“ Let me take this opportunity to congratulate all of you for a very successful digital version of CHI's Drug Discovery Chemistry! Viruses can't stop science nor our willingness to continue sharing the great work we scientists do. Thank you for your unwavering support and commitment to excellence! ”

Maricel Torrent, Principal Research Scientist, AbbVie



“ I was humbled to be there (Virtually) to share my knowledge and expertise. It was a great experience and I'm glad to be part of the meeting and was able to really catch up with my industry peers. ”

Dhanuka Wasalathanthri, PhD, Senior Scientist, Biologics Process Development, Bristol Myers Squibb Co.



Molecular Med TRI-CON

VIRTUAL CONFERENCE & EXPO

Connecting the Precision
Medicine Community

February 16-18, 2021

Register Today

TriConference.com

Pricing and Registration Information

REAL-TIME VIRTUAL CONFERENCE PRICING

(Includes Real-Time access to all Tri-Con virtual conferences & event features, and On-Demand access for one year.)

	Commercial	Academic, Government, Hospital-affiliated
Advance registration by January 22	\$999	\$599
Registration after January 22	\$1,199	\$699
FREE Pharma Pass - Limited Availability!	FREE	FREE

(Limited Complimentary Passes For Big Pharma, available until December 11. Employees of these companies qualify: Johnson & Johnson, Roche, Pfizer, Novartis, Merck, GlaxoSmithKline, Sanofi, AbbVie, Takeda, Bayer, Bristol Myers Squibb, AstraZeneca, Amgen, Gilead, Eli Lilly, Boehringer Ingelheim, Novo Nordisk, Teva, Allergan, Biogen.)

POST-EVENT ON-DEMAND CONFERENCE PRICING

(Includes post-event access to ALL conferences. Does not include Q&A sessions or networking.)

Advance registration by January 22	\$799	\$499
Registration after January 22	\$999	\$599

February 16 - 17, 2021	February 17 - 18, 2021
C1A: COVID-19 Diagnostics	C1B: COVID-19 Vaccines & Biotherapeutics
C2A: Circulating Tumor Cells and Liquid Biopsy	C2B: Point-of-Care Diagnostics
C3A: Immuno-Oncology Biomarkers	C3B: Clinical & Translational Biomarkers
C4A: Data, Analytics & AI for Precision Medicine Part 1	C4B: Data, Analytics & AI for Precision Medicine Part 2

CONFERENCE DISCOUNTS

Poster Submission - Discount (\$50 Off): Poster materials are due by January 15, 2021. Once your registration has been fully processed, we will send an email containing a unique link and instructions for submitting your abstract and other materials. If you do not receive your link within 5 business days, please contact jring@healthtech.com.

**this discount does not apply to product or service providers*

Alumni Discount: Cambridge Healthtech Institute (CHI) appreciates your past participation at Tri-Con. As a result of the great loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 20% off the registration rate.

Group Discounts: Discounts are available for multiple attendees from the same organization. For more information on group rates contact Bill Mote at +1-781-972-5479.

Healthtech Publishing

Complimentary news delivered to your inbox

Bio-IT World

News on the data deluge in petascale computing and the tools to deliver individualized medicine.

Bio-ITWorld.com

CLINICAL RESEARCH NEWS

Insights on the innovation between clinical trial management and delivery of care. ClinicalResearchNewsOnline.com

DiagnosticsWorld

Emerging Technologies in Diagnostics
DiagnosticsWorldNews.com



Reports designed to keep life science professionals informed of the salient trends in pharma technology, business, clinical development, and therapeutic disease markets

InsightPharmaReports.com
Contact Adriana Randall,
arandall@healthtech.com / +1-781-972-5402



Barnett is a recognized leader in clinical education, training, and reference guides for life science professionals involved in the drug development process. For more information, visit BarnettInternational.com.

ADDITIONAL REGISTRATION DETAILS

Each registration includes all conference sessions, posters and exhibits, and access to the on-demand library.

To view our Substitutions/Cancellations Policy, go to healthtech.com/regdetails

How to Register: **TriConference.com**

reg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288

Please use keycode
MMTC F
when registering!